New Alzheimer’s research from UVA Health suggests that enhanced light sensitivity may contribute to “sundowning” – the worsening of symptoms late in the day – and spur sleep disruptions thought to contribute to the disease’s progression.
Risk Adjusted Net Present Value: What is the current valuation of Aslan Pharmaceuticals’s Eblasakimab
The revenue for Eblasakimab is expected to reach an annual total of $430 mn by 2038 in the US based off GlobalDatas Expiry Model. The